Ipsen, an innovation-driven global specialty pharmaceutical group, announced that Dysport is now available in the United States for the treatment of cervical dystonia in adults. Dysport is the latest addition to the growing range of Ipsen’s drugs already available in North America, both in endocrinology with Somatuline Depot and Increlex, and in neurology, with Apokyn.
Christophe Jean, executive vice president, Operations of the Ipsen Group said, “The launch of Dysport in its therapeutic indication for the treatment of cervical dystonia in the United States is undoubtedly a significant milestone to strengthen Ipsen's presence in North America. We are very pleased to be able to offer physicians a new and important treatment option for their patients suffering from cervical dystonia. Dysport, together with Somatuline and Increlex, becomes Ipsen’s third product to be available globally. With the achievement of this key milestone, I wish to congratulate and thank the teams that are making this launch a reality thanks to their hard work and dedication reflective of an efficient organization.”
Dysport (abobotulinumtoxinA) inhibits release of the neurotransmitter acetylcholine from peripheral cholinergic nerve endings, which reduces muscular spasm.
Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200.